

**Tables**

|     |                  |  |
|-----|------------------|--|
| 11  | <b>Table 1:</b>  | Components of Per Member Per Year Cost Trend 1997-2002   |
| 14  | <b>Table 2:</b>  | Utilization of Common Drugs for the Top 25 Therapy Classes 2001-2002                                     |
| 19  | <b>Table 3:</b>  | Price Changes Due to Inflation for the Top 25 Therapy Classes 2001-2002                                  |
| 20  | <b>Table 4:</b>  | Price Changes for the Top 50 Common Brand Drugs 2001-2002  |
| 23  | <b>Table 5:</b>  | Price Changes Due to Therapeutic Mix for the Top 25 Therapy Classes 2001-2002                            |
| 25  | <b>Table 6:</b>  | Brand/Generic Mix for the Top 25 Therapy Classes 2001-2002   |
| 28  | <b>Table 7:</b>  | Changes in Units Per Prescription for the Top 25 Therapy Classes 2001-2002                               |
| 30  | <b>Table 8:</b>  | Top New Drugs in 2002  |
| 32  | <b>Table 9:</b>  | Percent of 2002 Ingredient Cost and Cost Per Prescription for the Top 50 New Drugs Introduced Since 1992 |
| 34  | <b>Table 10:</b> | Top 10 Therapy Classes Contributing to 2002 Trend  |
| 36  | <b>Table 11:</b> | 2001-2002 Summary and 2003-2007 Forecast for Major Therapy Classes                                       |
| 51  | <b>Table 12:</b> | Selected Infertility Products  |
| 67  | <b>Table A1:</b> | Cost Per Prescription and PMPY Cost for Major Therapy Classes 2001-2002                                  |
| 142 | <b>Table B1:</b> | Total Medicaid Prescription Cost 1996-2001   |
| 144 | <b>Table B2:</b> | PMPM Medicaid Prescription Drug Use 1996-2001  |
| 147 | <b>Table B3:</b> | Percent of Total Cost by Therapy Class, Medicaid vs. Commercial Population                               |

**Figures**

|    |                   |  |
|----|-------------------|--|
| 2  | <b>Figure 1:</b>  | National Health Expenditures for Selected Healthcare Accounts 1990 and 1993-2001   |
| 5  | <b>Figure 2:</b>  | 2002 Generic Conversion Rates for Glucophage® to Metformin and Market Share for Glucophage® and Metformin  |
| 5  | <b>Figure 3:</b>  | 2002 Generic Conversion Rates for Zestril®/Prinivil® to Lisinopril and Prinzide®/Zestoretic to Lisinopril/HCTZ and Market Share for Zestril®/Prinivil®, Prinzide®/Zestoretic, Lisinopril and Lisinopril/HCTZ |
| 6  | <b>Figure 4:</b>  | U.S. Sales for Brand Products With Patent Expirations Between 2003 and 2007  |
| 7  | <b>Figure 5:</b>  | Generic Fill Rate Fourth Quarter 1994 to Fourth Quarter 2007 (Estimated)   |
| 18 | <b>Figure 6:</b>  | Percent Change in Ingredient Cost Per Prescription Due to Inflation, Therapeutic Mix, Brand/Generic Mix and Units 2001-2002  |
| 29 | <b>Figure 7:</b>  | Impact of New Drugs Introduced Since 1992 on 2002 Utilization and Ingredient Cost  |
| 33 | <b>Figure 8:</b>  | Percent of Ingredient Cost Accounted for by New Drugs Introduced Since 1992  |
| 35 | <b>Figure 9:</b>  | Percent Changes in Ingredient Cost 1996-1997 to 2006-2007  |
| 49 | <b>Figure 10:</b> | Biotechnology Pipeline   |
| 62 | <b>Figure 11:</b> | Continuum of Approaches to Maximizing Generic Opportunities  |

|     |                    |   |
|-----|--------------------|---|
| 68  | <b>Figure A1:</b>  | Therapy Class Drug Market Share Trend — Gastrointestinals                                 |
| 75  | <b>Figure A2:</b>  | Therapy Class Drug Market Share Trend — Antidepressants                                   |
| 76  | <b>Figure A3:</b>  | Therapy Class Drug Market Share Trend — Antianxiety Agents                                |
| 77  | <b>Figure A4:</b>  | Therapy Class Drug Market Share Trend — Antipsychotics                                    |
| 80  | <b>Figure A5:</b>  | Therapy Class Drug Market Share Trend — Anti-Rheum (NSAIDs)                               |
| 82  | <b>Figure A6:</b>  | Therapy Class Drug Market Share Trend — Narcotic Analgesics                               |
| 83  | <b>Figure A7:</b>  | Therapy Class Drug Market Share Trend — Migraine Products                                 |
| 84  | <b>Figure A8:</b>  | Therapy Class Drug Market Share Trend — Anticonvulsants                                   |
| 88  | <b>Figure A9:</b>  | Therapy Class Drug Market Share Trend — Antihypertensives                                 |
| 89  | <b>Figure A10:</b> | Therapy Class Drug Market Share Trend — Calcium Blockers                                  |
| 90  | <b>Figure A11:</b> | Therapy Class Drug Market Share Trend — Beta Blockers                                     |
| 91  | <b>Figure A12:</b> | Therapy Class Drug Market Share Trend — Antihyperlipidemics                               |
| 94  | <b>Figure A13:</b> | Therapy Class Drug Market Share Trend — Asthmatics  |
| 95  | <b>Figure A14:</b> | Therapy Class Drug Market Share Trend — Antihistamines                                    |
| 96  | <b>Figure A15:</b> | Therapy Class Drug Market Share Trend — Decongestants/Nasal Steroids                      |
| 97  | <b>Figure A16:</b> | Therapy Class Drug Market Share Trend — Cough/Cold  |
| 100 | <b>Figure A17:</b> | Therapy Class Drug Market Share Trend — Cephalosporins                                    |
| 101 | <b>Figure A18:</b> | Therapy Class Drug Market Share Trend — Macrolides  |
| 102 | <b>Figure A19:</b> | Therapy Class Drug Market Share Trend — Penicillins                                       |
| 103 | <b>Figure A20:</b> | Therapy Class Drug Market Share Trend — Quinolones  |
| 105 | <b>Figure A21:</b> | Therapy Class Drug Market Share Trend — Antivirals  |
| 109 | <b>Figure A22:</b> | Therapy Class Drug Market Share Trend — Oral Contraceptives                               |
| 110 | <b>Figure A23:</b> | Therapy Class Drug Market Share Trend — Estrogens   |
| 112 | <b>Figure A24:</b> | Therapy Class Drug Market Share Trend — Miscellaneous Endocrines                          |
| 114 | <b>Figure A25:</b> | Therapy Class Drug Market Share Trend — Dermatologicals                                   |
| 118 | <b>Figure A26:</b> | Therapy Class Drug Market Share Trend — Oral Antidiabetics                                |
| 119 | <b>Figure A27:</b> | Therapy Class Drug Market Share Trend — Insulins  |
| 121 | <b>Figure A28:</b> | Therapy Class Drug Market Share Trend — Anticancer  |
| 132 | <b>Figure B1:</b>  | Medicaid Enrollment Sectors 2001  |
| 137 | <b>Figure B2:</b>  | Growth of Enrollment in Medicaid Managed Care Programs by Percent of Recipients 1991-2001 |
| 140 | <b>Figure B3:</b>  | Medicaid Spending as a Percent of Health Spending 1998                                    |
| 141 | <b>Figure B4:</b>  | Growth Rates in Each Type of Expenditure 1998-2000  |
| 144 | <b>Figure B5:</b>  | Total Medicaid Prescription Drug Costs vs. Number of Enrollees 1996-2001                  |
| 146 | <b>Figure B6:</b>  | Medicaid PMPM Utilization vs. Cost Per Rx 1996-2001                                       |